» Articles » PMID: 38910326

Preclinical Evidence in the Assembly of Mammalian SWI/SNF Complexes: Epigenetic Insights and Clinical Perspectives in Human Lung Disease Therapy

Overview
Journal Mol Ther
Publisher Cell Press
Date 2024 Jun 24
PMID 38910326
Authors
Affiliations
Soon will be listed here.
Abstract

The SWI/SNF complex, also known as the BRG1/BRM-associated factor (BAF) complex, represents a critical regulator of chromatin remodeling mechanisms in mammals. It is alternatively referred to as mSWI/SNF and has been suggested to be imbalanced in human disease compared with human health. Three types of BAF assemblies associated with it have been described, including (1) canonical BAF (cBAF), (2) polybromo-associated BAF (PBAF), and (3) non-canonical BAF (ncBAF) complexes. Each of these BAF assemblies plays a role, either functional or dysfunctional, in governing gene expression patterns, cellular processes, epigenetic mechanisms, and biological processes. Recent evidence increasingly links the dysregulation of mSWI/SNF complexes to various human non-malignant lung chronic disorders and lung malignant diseases. This review aims to provide a comprehensive general state-of-the-art and a profound examination of the current understanding of mSWI/SNF assembly processes, as well as the structural and functional organization of mSWI/SNF complexes and their subunits. In addition, it explores their intricate functional connections with potentially dysregulated transcription factors, placing particular emphasis on molecular and cellular pathogenic processes in lung diseases. These processes are reflected in human epigenome aberrations that impact clinical and therapeutic levels, suggesting novel perspectives on the diagnosis and molecular therapies for human respiratory diseases.

Citing Articles

SMARCB1-driven EGFR-GLI1 epigenetic alterations in lung cancer progression and therapy are differentially modulated by MEOX2 and GLI-1.

Trejo-Villegas O, Pineda-Villegas P, Armas-Lopez L, Mendoza-Milla C, Peralta-Arrieta I, Arrieta O Cancer Gene Ther. 2025; .

PMID: 39971779 DOI: 10.1038/s41417-025-00873-0.


RNA and epigenetic editing: The new frontier in gene and cell therapy.

Avila-Moreno F, Giangrande P Mol Ther. 2025; 33(2):424-425.

PMID: 39842430 PMC: 11852672. DOI: 10.1016/j.ymthe.2025.01.017.


SWItch/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy.

Gu Y, Lai S, Yang J, Zhang J, Fan X, Zheng Q Transl Lung Cancer Res. 2024; 13(10):2660-2672.

PMID: 39507018 PMC: 11535837. DOI: 10.21037/tlcr-24-339.

References
1.
Wang W, Cote J, Xue Y, Zhou S, Khavari P, Biggar S . Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 1996; 15(19):5370-82. PMC: 452280. View

2.
Braun C, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M . Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014; 6(227):227ra33. DOI: 10.1126/scitranslmed.3007280. View

3.
Brien G, Remillard D, Shi J, Hemming M, Chabon J, Wynne K . Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018; 7. PMC: 6277197. DOI: 10.7554/eLife.41305. View

4.
Fernando T, Piskol R, Bainer R, Sokol E, Trabucco S, Zhang Q . Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat Commun. 2020; 11(1):5551. PMC: 7609548. DOI: 10.1038/s41467-020-19402-8. View

5.
Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View